ABUS

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing therapies for chronic hepatitis B virus (HBV) infection.

Headquartered in Pennsylvania, the company’s pipeline includes RNA interference (RNAi) therapeutics, capsid inhibitors, and immune modulators aimed at achieving a functional cure for HBV.

Arbutus also holds a portfolio of lipid nanoparticle (LNP) delivery technologies, which have been licensed for use in certain mRNA-based therapeutics.